EXAS Stock Recent News

Exact Sciences Corporation (NASDAQ:EXAS ) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Catherine Schulte - Baird Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Jack Meehan - Nephron Research Andrew Brackmann - William Blair Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Subu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Dan Leonard - UBS Bill Bonello - Craig Hallum Sung Ji Nam - Scotiabank Eve Burstein - Bernstein Research Andrew Cooper - Raymond James Kyle Mikson - Canaccord Operator Good day, everyone, and welcome to the Exact Sciences Fourth Quarter 2024 Earnings Call. Today's call is being recorded.

Exact Sciences (EXAS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.27 per share a year ago.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $713 million for the fourth quarter of 2024 and $2.76 billion for the full year of 2024, both ended December 31, 2024. “The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “This year is on track t.

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that the U.S. Patent Trial and Appeal Board instituted inter partes review of U.S. Patent No. 11,970,746 owned by Exact Sciences.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) meeting January 23-25, 2025, in San Francisco. “The data we are presenting at ASCO GI underscore Exact Sciences' leadership in advancing scientific innovation to drive meaningful progress in cancer detection and patient care,” said Jorge Garces, PhD, ch.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared clinical validation data for its OncodetectTM MRD test at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI.) Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity dur.